Fairmount Funds Management LLC - 29 May 2025 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Reporting relationship: Director
Issuer ticker: SYRE
Reported as of: 29 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2025, 16:39:53 UTC
Prior SEC filing: 01 May 2025
Next SEC filing: 03 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC

Key filing fact

Fairmount Funds Management LLC filed Form 4 for Spyre Therapeutics, Inc. (SYRE) on 02 Jun 2025.

Key facts

This page summarizes Fairmount Funds Management LLC's Form 4 filing for Spyre Therapeutics, Inc. (SYRE).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 02 Jun 2025, 16:39.

Change

Previous filing in this sequence was filed on 01 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (4)

CIK 0001802528 Primary reporting owner

Fairmount Funds Management LLC

Relationship: Director
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Signature date: 02 Jun 2025

CIK 0001663607

Harwin Peter Evan

Relationship: Director
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Tomas Kiselak
Signature date: 02 Jun 2025

CIK 0001830177

Kiselak Tomas

Relationship: Director
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Peter Harwin
Signature date: 02 Jun 2025

CIK 0001769651

Fairmount Healthcare Fund II L.P.

Relationship: Director
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II L.P.
Signature date: 02 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SYRE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +25,000
Change %
Price: $0.000000
Shares after: 25,000
Date: 29 May 2025
Ownership: By Peter Harwin
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $15.55
Footnotes: F1, F2

SYRE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +25,000
Change %
Price: $0.000000
Shares after: 25,000
Date: 29 May 2025
Ownership: By Tomas Kiselak
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $15.55
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to Peter Harwin's continuous service with the Issuer at each vesting date.

Footnote F2

Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Harwin holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein.

Footnote F3

This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to Tomas Kiselak's continuous service with the Issuer at each vesting date.

Footnote F4

Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Kiselak holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein.

SEC remarks

The Adviser and Fairmount Healthcare Fund II L.P. may each be deemed a director by deputization of Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of the Issuer and are also each a Managing Member of the Adviser.